French dairy group Lactalis plans to invest a total of EUR34.6m (US$51.3m) over the next three years to build its business in the baby formula category.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
At its Bridel subsidiary, Lactalis will invest EUR7.1m to establish a new research and development centre, to open at the end of 2010.
One of its fields of study will be the medical applications of baby milk production, a Lactalis spokesman told just-food today (13 November).
“Since we acquired the Celia brand in 2006, our activities in the baby milk segment have developed significantly and a strong R&D capability has become imperative,” he said.
The investment programme also makes provision for the creation in 2011-2012 of a EUR15m production unit for lactose derivatives used in baby food and pharmaceuticals.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAt the company’s major bottling and packaging facility for the Lactel, Eveil, Bridelice and Président dairy brands, a further EUR12.5m has been earmarked for the construction of a new production line and an incubator for aseptic products, particularly for baby milk formulated for special medical purposes.
